Opioid painkillers, long regarded as some of the most effective treatments for acute pain, may offer far less benefit than many people expect, according to the largest review of its kind. Researchers found that these widely prescribed medications often provide only modest, short-term pain relief and, for many common conditions, offer little or no meaningful advantage over placebo.
The study, published in the journal Drugs, was led by researchers at the University of Sydney. It analyzed evidence from 59 systematic reviews covering more than 50 acute pain conditions in both children and adults, making it the most comprehensive assessment to date of the benefits and risks of opioid painkillers such as codeine, morphine, oxycodone, and tramadol.
Examining the Evidence Across Dozens of Conditions
The researchers pooled data from existing systematic reviews to evaluate how well oral opioids relieve acute pain and how frequently they cause adverse effects.
The analysis covered a wide range of conditions, including musculoskeletal injuries, post-surgical pain, childbirth, kidney stones, dental procedures, and other forms of acute pain commonly treated with prescription opioids.
The review comes as many countries continue efforts to reduce unnecessary opioid prescribing in response to rising rates of dependence, overdose, and opioid-related deaths.
Modest Relief for Some Types of Acute Pain
Overall, the researchers found that oral opioids were only slightly more effective than placebo for acute musculoskeletal pain, including back pain and limb injuries, during the first six to 48 hours after treatment began.
Even when benefits were observed, pain relief generally lasted only a few hours.
The review found modest short-term benefits for several conditions, including pain following dental surgery, ear procedures, certain traumatic limb injuries, childbirth, cesarean delivery, abdominal pain, and bunion surgery.
However, the researchers found little or no meaningful benefit for several other common causes of acute pain.
These included some forms of limb surgery, pain caused by kidney stones, discomfort after tonsil removal, and pain experienced by newborns receiving assisted ventilation.
For several additional conditions—including heart-related chest pain, pain following hysterectomy, and topical opioid patches used for skin conditions—the available evidence was either inconsistent or too limited to draw reliable conclusions.
Side Effects Were Common
Alongside their relatively modest benefits, opioids were frequently associated with a higher risk of adverse effects.
The most commonly reported side effects included nausea and vomiting, particularly among patients treated for acute musculoskeletal injuries, traumatic limb injuries, and certain types of postoperative pain.
The researchers caution that the true frequency of side effects may actually be higher because many clinical trials did not consistently or comprehensively report adverse events.
Incomplete safety reporting makes it more difficult to accurately assess the risks associated with short-term opioid treatment.
Dependence Can Develop Quickly
Although opioids may still be appropriate for severe acute pain in carefully selected situations, the researchers emphasize that even short-term prescribing carries important risks.
Repeated use may lead to tolerance, physical dependence, misuse, overdose, hospitalization, and death—problems that continue to drive the ongoing opioid crisis in several countries.
The review also highlights growing evidence that persistent opioid use can begin surprisingly early.
In some patients, ongoing opioid use develops soon after the initial prescription, even when the medication was originally intended only for temporary pain relief.
The authors therefore recommend that patients receive clear information about both the potential benefits and risks before starting opioid treatment.
When opioids are considered necessary, they should be prescribed at the lowest effective dose and for the shortest duration needed to control pain.
What the Findings Mean
The researchers note that many of the clinical trials included in the review evaluated only single opioid doses rather than the repeated dosing patterns commonly seen in everyday medical practice.
As a result, additional research is needed to better understand the effects of typical prescribing patterns and the long-term consequences of short courses of opioid treatment.
The findings also reinforce recent clinical guidelines that increasingly recommend non-opioid treatments—including paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), and physical therapies—as first-line options for many forms of acute pain.
For healthcare systems and policymakers, the review supports continued efforts to improve prescribing practices, strengthen monitoring, and expand access to safer pain-management strategies.
Overall, the researchers argue that opioids should no longer be viewed as the automatic or most effective solution for acute pain. Instead, the evidence suggests they have a more limited role, with benefits that must be carefully weighed against their well-established risks.
